4.91
Ardelyx Inc stock is traded at $4.91, with a volume of 5.71M.
It is down -0.41% in the last 24 hours and down -8.40% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$4.93
Open:
$4.83
24h Volume:
5.71M
Relative Volume:
1.40
Market Cap:
$1.16B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-15.67
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-6.48%
1M Performance:
-8.40%
6M Performance:
-28.74%
1Y Performance:
-32.74%
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ARDX
Ardelyx Inc
|
4.91 | 1.16B | 251.85M | -72.58M | -63.80M | -0.3134 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
Mar-04-25 | Initiated | BTIG Research | Buy |
Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Apr-05-24 | Initiated | Leerink Partners | Outperform |
Dec-18-23 | Initiated | Raymond James | Strong Buy |
Sep-07-23 | Initiated | H.C. Wainwright | Buy |
Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
Mar-23-21 | Initiated | Wedbush | Outperform |
Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
Oct-20-20 | Resumed | Citigroup | Buy |
Feb-18-20 | Resumed | Jefferies | Buy |
Feb-12-20 | Initiated | Citigroup | Buy |
Feb-10-20 | Initiated | Cowen | Outperform |
Apr-08-19 | Initiated | Piper Jaffray | Overweight |
Aug-24-18 | Initiated | Jefferies | Buy |
Mar-19-18 | Resumed | Leerink Partners | Outperform |
Nov-29-17 | Reiterated | Citigroup | Buy |
Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
Oct-17-17 | Resumed | Leerink Partners | Outperform |
Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times
Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns “Buy” Rating from LADENBURG THALM/SH SH - Defense World
Ardelyx CEO Michael Raab sells $223,198 in stock - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential By Investing.com - Investing.com South Africa
Ardelyx, Inc. to Host Earnings Call - ACCESS Newswire
Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings - Defense World
Ardelyx (NASDAQ:ARDX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
Rhumbline Advisers Purchases 6,070 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx (NASDAQ:ARDX) Coverage Initiated by Analysts at BTIG Research - Defense World
BTIG sets Ardelyx stock Buy rating, $14 price target - Investing.com India
BTIG sets Ardelyx stock Buy rating, $14 price target By Investing.com - Investing.com South Africa
BTIG Initiates Ardelyx at Buy With $14 Price Target -March 04, 2025 at 07:10 am EST - Marketscreener.com
BTIG initiates Ardelyx with a Buy, sees attractive entry point after pullback - TipRanks
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Shareholders That Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class ActionARDX - ACCESS Newswire
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - ACCESS Newswire
Los Angeles Capital Management LLC Has $2.38 Million Stock Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying Activity - MarketBeat
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Insider Buying: Ardelyx, Inc. (NASDAQ:ARDX) Director Buys 77,729 Shares of Stock - MarketBeat
Wedbush Estimates Ardelyx's FY2029 Earnings (NASDAQ:ARDX) - MarketBeat
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):